Home

DEBORAH J ANDREWS

CIK 1325697 · Chief Financial Officer & EVP · last filed 2026-08-18

DEBORAH J ANDREWS is a Chief Financial Officer & EVP who has filed 57 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for STAA, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$6.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $916.8K across reported positions. 20 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$916.8K

Companies

3

Total Filings

57

Lifetime Open-Market Net

-$6.82M

Filer Profile

Reported Address
1911 WALKER AVE.
MONROVIA, CA 91016
Related Filers
Lineage Cell Therapeutics, Inc. — 20 joint filings, latest 2026-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STAA Chief Financial Officer & EVP 38,910 $22.66 $881.7K -$6.79M 38 2026-08-18
LCTX Director 34,720 $1.01 $35.1K -$56.1K 8 2026-07-02
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Director 10,000 — — $27.7K 10 2018-09-13

Recent Filings

57 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-18 STAA Mixed +2,571 -$69.7K EDGAR
2026-08-04 STAA Mixed +17,686 -$459.9K EDGAR
2026-07-02 LCTX Grant (A) — $0 EDGAR
2026-05-19 STAA Mixed +10,067 -$180.6K EDGAR
2026-03-16 STAA Grant (A) — $0 EDGAR
2026-02-04 STAA Grant (A) — $0 EDGAR
2025-07-02 LCTX Grant (A) — $0 EDGAR
2025-06-26 STAA Grant (A) — $0 EDGAR
2024-07-03 LCTX Grant (A) — $0 EDGAR
2023-07-03 LCTX Grant (A) — $0 EDGAR
Showing 1–10 of 57
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.